# Royalty Pharma (RPRX) — Analyst Forecast

RPRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rprx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 8 | 2 | 0 | 10 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $62.00 | $65.67 | $68.00 | 3 |

Last price $59.62 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | $67.00 |
| Sep 8, 2026 | TD Cowen | Maintained | Buy | $68.00 |
| Aug 7, 2026 | JP Morgan | Maintained | Overweight | $62.00 |
| Jul 13, 2026 | TD Cowen | Maintained | Buy | $65.00 |
| May 7, 2026 | JP Morgan | Maintained | Overweight | $58.00 |
| May 7, 2026 | Citigroup | Maintained | Buy | $66.00 |
| Apr 21, 2026 | UBS | Maintained | Buy | $57.00 |
| Apr 10, 2026 | Morgan Stanley | Maintained | Overweight | $63.00 |
| Jan 27, 2026 | Citigroup | Maintained | Buy | $50.00 |
| Dec 11, 2025 | TD Cowen | Maintained | Buy | $45.00 |
| Oct 10, 2025 | Morgan Stanley | Maintained | Overweight | $54.00 |
| Sep 30, 2025 | Goldman Sachs | Initiated Coverage | Buy | $42.00 |
| Jul 22, 2025 | Citigroup | Maintained | Buy | $42.00 |
| Jul 10, 2025 | Morgan Stanley | Maintained | Overweight | $54.00 |
| Oct 25, 2024 | Citigroup | Maintained | Buy | $40.00 |
| Aug 14, 2024 | Goldman Sachs | Maintained | Buy | $51.00 |
| Jul 11, 2024 | Morgan Stanley | Maintained | Overweight | $51.00 |
| Jun 3, 2024 | UBS | Downgraded | Buy → Neutral | $28.00 |
| Apr 12, 2024 | B of A Securities | Maintained | Buy | $38.00 |
| Feb 20, 2024 | Goldman Sachs | Maintained | Buy | $50.00 |

## Frequently Asked Questions

### What is the price target for RPRX stock?

The average 12-month analyst price target for Royalty Pharma (RPRX) is $65.67, with a high estimate of $68.00 and a low of $62.00, across 3 analysts.

### Is RPRX a buy, sell, or hold?

Analysts covering Royalty Pharma currently average a Buy rating: 8 buy, 2 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for RPRX?

The average price target of $65.67 implies 10.14% upside from the last price of $59.62.

### What is the latest analyst rating on RPRX?

On Oct 7, 2026, Morgan Stanley maintained Royalty Pharma at Overweight with a price target of $67.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).